GB2487699B - Targeted polypropyleneimine dendrimers for use in the treatment of cancer - Google Patents

Targeted polypropyleneimine dendrimers for use in the treatment of cancer

Info

Publication number
GB2487699B
GB2487699B GB1209228.4A GB201209228A GB2487699B GB 2487699 B GB2487699 B GB 2487699B GB 201209228 A GB201209228 A GB 201209228A GB 2487699 B GB2487699 B GB 2487699B
Authority
GB
United Kingdom
Prior art keywords
targeted
cancer
treatment
polypropyleneimine dendrimers
polypropyleneimine
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
GB1209228.4A
Other versions
GB2487699A (en
GB201209228D0 (en
Inventor
Myriam Dufes Christine
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
University of Strathclyde
Original Assignee
University of Strathclyde
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by University of Strathclyde filed Critical University of Strathclyde
Publication of GB201209228D0 publication Critical patent/GB201209228D0/en
Publication of GB2487699A publication Critical patent/GB2487699A/en
Application granted granted Critical
Publication of GB2487699B publication Critical patent/GB2487699B/en
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
    • A61K47/59—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
    • A61K47/543—Lipids, e.g. triglycerides; Polyamines, e.g. spermine or spermidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
GB1209228.4A 2009-10-27 2010-10-27 Targeted polypropyleneimine dendrimers for use in the treatment of cancer Expired - Fee Related GB2487699B (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB0918822.8A GB0918822D0 (en) 2009-10-27 2009-10-27 Targeted dendrimers
PCT/GB2010/001990 WO2011051667A1 (en) 2009-10-27 2010-10-27 Targeted dendrimers

Publications (3)

Publication Number Publication Date
GB201209228D0 GB201209228D0 (en) 2012-07-04
GB2487699A GB2487699A (en) 2012-08-01
GB2487699B true GB2487699B (en) 2017-08-23

Family

ID=41426768

Family Applications (2)

Application Number Title Priority Date Filing Date
GBGB0918822.8A Ceased GB0918822D0 (en) 2009-10-27 2009-10-27 Targeted dendrimers
GB1209228.4A Expired - Fee Related GB2487699B (en) 2009-10-27 2010-10-27 Targeted polypropyleneimine dendrimers for use in the treatment of cancer

Family Applications Before (1)

Application Number Title Priority Date Filing Date
GBGB0918822.8A Ceased GB0918822D0 (en) 2009-10-27 2009-10-27 Targeted dendrimers

Country Status (2)

Country Link
GB (2) GB0918822D0 (en)
WO (1) WO2011051667A1 (en)

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2006040579A1 (en) * 2004-10-14 2006-04-20 The University Court Of The University Of Glasgow Bioactive polymers
WO2008010000A1 (en) * 2006-07-21 2008-01-24 National Center For Scientific Research Molecular dendritic transporters

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0125216D0 (en) 2001-10-19 2001-12-12 Univ Strathclyde Dendrimers for use in targeted delivery

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2006040579A1 (en) * 2004-10-14 2006-04-20 The University Court Of The University Of Glasgow Bioactive polymers
WO2008010000A1 (en) * 2006-07-21 2008-01-24 National Center For Scientific Research Molecular dendritic transporters

Non-Patent Citations (9)

* Cited by examiner, † Cited by third party
Title
BHADRA, D. YADAV, A.K. BHADRA, S. JAIN, N.K.: "Glycodendrimeric nanoparticulate carriers of primaquine phosphate for liver targeting", INTERNATIONAL JOURNAL OF PHARMACEUTICS, ELSEVIER, AMSTERDAM, NL, vol. 295, no. 1-2, 13 May 2005 (2005-05-13), AMSTERDAM, NL, pages 221 - 233, XP004852857, ISSN: 0378-5173, DOI: 10.1016/j.ijpharm.2005.01.026 *
DUTTA T ET AL: "Targeting of efavirenz loaded tuftsin conjugated poly (propyleneimine) dendrimers to HIV infected macrophages in vitro", EUROPEAN JOURNAL OF PHARMACEUTICAL SCIENCES, ELSEVIER, AMSTERDAM, NL, vol. 34... *
DUTTA, T. JAIN, N.K.: "Targeting potential and anti-HIV activity of lamivudine loaded mannosylated poly (propyleneimine) dendrimer", BIOCHIMICA ET BIOPHYSICA ACTA (BBA) - GENERAL SUBJECTS, ELSEVIER, AMSTERDAM, NL, vol. 1770, no. 4, 22 February 2007 (2007-02-22), AMSTERDAM, NL, pages 681 - 686, XP005900244, ISSN: 0304-4165, DOI: 10.1016/j.bbagen.2006.12.007 *
ELLEN M.M. DE BRABANDER-VAN DEN BERG, E.W. MEIJER: "Poly(propylene imine) Dendrimers: Large-Scale Synthesis by Heterogeneously Catalyzed Hydrogenations", ANGEWANDTE CHEMIE INTERNATIONAL EDITION, WILEY-VCH VERLAG GMBH, vol. 32, no. 9, 1 September 1993 (1993-09-01), pages 1308 - 1311, XP000394242, ISSN: 1433-7851, DOI: 10.1002/anie.199313081 *
HUANG, R. KE, W. LIU, Y. JIANG, C. PEI, Y.: "The use of lactoferrin as a ligand for targeting the polyamidoamine-based gene delivery system to the brain", BIOMATERIALS., ELSEVIER SCIENCE PUBLISHERS BV., BARKING., GB, vol. 29, no. 2, 1 November 2007 (2007-11-01), GB, pages 238 - 246, XP022323374, ISSN: 0142-9612, DOI: 10.1016/j.biomaterials.2007.09.024 *
SCHATZLEIN, ANDREAS G., ELOUZI, ABDURAHIM, DUFES, CHRISTINE, ZINSELMEYER, BERND H., UCHEGBU, IJEOMA F.: "Targeted tumor gene deliveryusing synthetic polypropylenimine dendrimer delivery systems", AMERICAN ASSOCIATION FOR CANCER RESEARCH. PROCEEDINGS OF THE ANNUAL MEETING, AMERICAN ASSOCIATION FOR CANCER RESEARCH, US, vol. 45, 2346, 1 January 2004 (2004-01-01), US, pages 1 - 2, XP008133315, ISSN: 0197-016X *
SWATI KOPPU, YEW JINN OH, RUANGELIE EDRADA-EBEL, DAVID R. BLATCHFORD, LAURENCE TETLEY, ROTHWELLE J. TATE AND CHRISTINE DUFÈS: "Tumor regression after systemic administration of a novel tumor-targeted gene delivery system carrying a therapeutic plasmid DNA", JOURNAL OF CONTROLLED RELEASE., ELSEVIER, AMSTERDAM., NL, vol. 143, no. 2, 19 April 2010 (2010-04-19), NL, pages 215 - 221, XP002623923, ISSN: 0168-3659, DOI: 10.1016/j.jconrel.2009.11.015 *
TARATULA, O. ; GARBUZENKO, O.B. ; KIRKPATRICK, P. ; PANDYA, I. ; SAVLA, R. ; POZHAROV, V.P. ; HE^N, H. ; MINKO, T.: "Surface-engineered targeted PPI dendrimer for efficient intracellular and intratumoral siRNA delivery", JOURNAL OF CONTROLLED RELEASE., ELSEVIER, AMSTERDAM., NL, vol. 140, no. 3, 16 December 2009 (2009-12-16), NL, pages 284 - 293, XP026778506, ISSN: 0168-3659, DOI: 10.1016/j.jconrel.2009.06.019 *
ZILI SIDERATOUA, CHRISTINA KONTOYIANNI, GARYFALIA I. DROSSOPOULOU AND CONSTANTINOS M. PALEOS: "Synthesis of a folate functionalized PEGylated poly(propylene imine) dendrimer as prospective targeted drug delivery system", BIOORGANIC & MEDICINAL CHEMISTRY LETTERS, PERGAMON, AMSTERDAM, NL, vol. 20, no. 22, 1 November 2010 (2010-11-01), AMSTERDAM, NL, pages 6513 - 6517, XP002623922, ISSN: 0960-894X, DOI: 10.1016/J.BMCL.2010.09.058 *

Also Published As

Publication number Publication date
WO2011051667A1 (en) 2011-05-05
GB2487699A (en) 2012-08-01
GB0918822D0 (en) 2009-12-09
GB201209228D0 (en) 2012-07-04

Similar Documents

Publication Publication Date Title
ZA201207574B (en) Phytocannabinoids in the treatment of cancer
HK1175476A1 (en) Cancer treatment
IL218575A0 (en) Treatment of cancer
IL228597A0 (en) Isoindoline compounds for use in the treatment of cancer
IL215108A0 (en) Amatoxin-armed target-binding moieties for the treatment of cancer
IL217291A0 (en) Exosome based treatment of cancer
PL2427441T3 (en) Pkm2 activators for use in the treatment of cancer
IL218987A0 (en) Methods and compositions for treating cancer
IL224370B (en) Combination treatment for prostate carcinoma
GB0921596D0 (en) Particles for the treatment of cancer in combination with radiotherapy
HK1159498A1 (en) Methods and compositions for the treatment of cancer
EP2461814A4 (en) Treatment of prostate cancer
ZA201107879B (en) Composition for the treatment of prostate cancer
EP2419136A4 (en) Compositions and methods for treating cancer
EP2340027A4 (en) Methods and compositions for the treatment of cancer
IL214349A0 (en) Compositions and methods for the treatment of cancer
HK1256479A1 (en) Grn163l for use as telomerase inhibitor in the treatment of cancer
EP2437738A4 (en) Methods and compositions for the treatment of cancer
ZA201209452B (en) Gold complexes for use in the treatment of cancer
EP2575863A4 (en) Use of the sparc microenvironment signature in the treatment of cancer
EP2411031A4 (en) Methods and compositions for the treatment of cancer
ZA201202657B (en) Use of the sparc microenvironment signature in the treatment of cancer
GB201718726D0 (en) Phytocannabinoids in the treatment of cancer
GB0916686D0 (en) Treatment of cancer
GB2487699B (en) Targeted polypropyleneimine dendrimers for use in the treatment of cancer

Legal Events

Date Code Title Description
PCNP Patent ceased through non-payment of renewal fee

Effective date: 20221027